User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8070

Interactions with Platform & by Email *

INTERACTIONS

1130

Unique # Participated *

PARTICIPANTS

242

Responses Validated *

VALIDATIONS

46

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Anxiety Disorders: A Prelude.....II-1
Future Outlook – Market Challenged by Generics and Efficacy Issues.....II-1
1$100
   A Snapshot of the Global Market Opportunity.....II-2
Prevalence of Specific Anxiety Disorders.....II-2
Generalized Anxiety Disorder (GAD).....II-2
Obsessive-Compulsive Disorder (OCD).....II-2
Specific Phobias.....II-2
Social Phobias.....II-2
1$100
   Panic Disorder.....II-3
Post Traumatic Stress Disorder (PTSD).....II-3
Social Anxiety Disorder (SAD).....II-3
Anxiety Disorders Can Strike At Any Age.....II-3
Shyness: A Form of Anxiety Disorder among Kids and Teenagers.....II-3
1$100
   Table 1: Average Age of Onset for Select Anxiety Disorders (includes corresponding Graph/Chart).....II-4
Women - The Most Affected Lot with Anxiety.....II-4
Table 2: Female to Male Ratio for Incidence of Anxiety Disorders by Type of Disorder (includes corresponding Graph/Chart).....II-4
1$350
   Patent Expiries – A Major Impediment to Market Growth.....II-5
Patent Expiries of Select Leading Drugs Indicated for Anxiety Disorders.....II-5
Leading Drugs and Indications for Anxiety Disorders.....II-5
2$125
   Pharmacological Treatment.....II-71$100
   Available Treatment for Anxiety Disorders – In a Nutshell.....II-8
Antidepressants for Anxiety Disorders.....II-8
Selective Serotonin Reuptake Inhibitors (SSRIs).....II-8
1$100
   Zoloft (Sertraline).....II-9
Paxil (Paroxetine).....II-9
Prozac (Fluoxetine).....II-9
Cipralex/Lexapro (Escitalopram).....II-9
Competitive Scenario - Cymbalta Emerges as a Market Leader in Anti-Depressants
  Market.....II-9
1$100
   Table 3: Select Leading Anti-Depressants indicated for Anxiety Disorders (2007-2009): Annual Revenues for Cymbalta, Lexapro, Paxil & Wellbutrin, Effexor, Zoloft, and Remeron in US$ Million (includes corresponding Graph/Chart).....II-101$350
   Serotonin and Norepinephrine Reuptake Inhibitors (SNRI).....II-11
Cymbalta (Duloxetine).....II-11
Effexor (Venlafaxine).....II-11
Monoamine Oxidase Inhibitors (MAOIs).....II-11
Tricyclic and Tetracyclic Antidepressants (TCAs).....II-11
1$100
   Other Antidepressants.....II-12
Sedatives.....II-12
Benzodiazepines (BZDs).....II-12
Other Medications.....II-12
Obsessive Compulsive Disorder (OCD) Treatment.....II-12
1$100
   Table 4: Dosing of Select Serotonin Reuptake Inhibitors in OCD Treatment.....II-13
Generalized Anxiety Disorder (GAD) Treatment.....II-13
1$350
   Drugs Indicated for the Treatment of Generalized Anxiety Disorder (GAD).....II-141$100
   Novel Therapies for GAD on the Anvil.....II-15
Novel Compounds Under Investigation for Generalized Anxiety Disorder (GAD).....II-15
1$100
   Select Anti-Anxiety Pipeline Drugs in Phase III Development Stage and Filed for
  Approval.....II-16
Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage.....II-16
1$100
   Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage.....II-171$100
   Psychological Treatment.....II-18
Cognitive Behavioral Therapy.....II-18
Relaxation Techniques.....II-18
Biofeedback.....II-18
Hypnotherapy.....II-18
Meditation.....II-18
1$100
   Natural Remedies for Treating Anxiety.....II-19
Acupuncture.....II-19
Other Treatment Options.....II-19
Support Program.....II-19
Changes in Lifestyle.....II-19
1$100
   What is Anxiety Disorder?.....II-20
Types of Anxiety Disorders.....II-20
A Review of Anxiety Disorders.....II-20
Generalized Anxiety Disorder (GAD).....II-20
1$100
   Panic Disorder.....II-21
Phobias.....II-21
Agoraphobia.....II-21
1$100
   Social Phobia.....II-22
Obsessive-Compulsive Disorder (OCD).....II-22
1$100
   Symptoms, Obsessions and Compulsions of Obsessive-Compulsive Disorder.....II-231$100
   Particular Phobic Anxiety Disorder (PPAD).....II-24
Post-Traumatic Stress Disorder (PTSD).....II-24
Separation Anxiety Disorder (SAD).....II-24
Anxiety Disorders in Children.....II-24
1$100
   Anxiety Disorders in Teens.....II-25
Causes and Factors for Anxiety Disorder.....II-25
1$100
   Symptoms.....II-261$100
   Diagnosis for Anxiety Disorders.....II-271$100
   Sun Pharma Receives FDA Approval to Commercialize Generic Cymbalta.....II-28
Impax Receives Tentative FDA Approval for Generic Version of Cymbalta.....II-28
Actavis Receives FDA Approval for Alprazolam.....II-28
Sun Pharma Receives FDA Approval to Generic Version of Alprazolam.....II-28
Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK.....II-28
1$100
   Coenzyme-A Technologies Introduces MODULATOR MATRIX I.....II-29
Sun Pharma to Launch Generic Version of Venlafaxine.....II-29
Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD.....II-29
Aurobindo Pharma Receives Tentative US FDA Approval for Escitalopram.....II-29
Boehringer Ingelheim and Eli Lilly Obtain Approval for Cymbalta in Canada.....II-29
1$100
   Medtronic's Reclaim Deep Brain Stimulation Therapy Receives CE-Mark Approval.....II-30
Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA.....II-30
Servier Obtains EMEA Approval for Valdoxan in Treating Major Depressive
  Episodes.....II-30
1$100
   Boehringer Ingelheim and Eli Lilly Receive EU Approval for Cymbalta in GAD.....II-31
AstraZeneca Files for Approval of Seroquel XR for GAD in Europe.....II-31
1$100
   Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride Tablets.....II-32
Jazz Pharma Launches Once-A-Day LUVOX® CR Extended-Release Capsules.....II-32
1$100
   Euthymics Acquires DOV Pharma.....II-33
Abbott Acquires Solvay Pharmaceuticals.....II-33
Pfizer Withdraws sNDA for Lyrica in Treating GAD.....II-33
1$100
   Eli Lilly Drags Sun Pharma to Court for Alleged Infringment of Cymbalta Patent.....II-34
Pfizer Discontinues Late Stage Development of GAD Drug Candidate.....II-34
Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals.....II-34
GSK Inks Agreement for Divesting Wellbutrin XL® Rights to Biovail
  International.....II-34
1$100
   Ligand Pharmaceuticals Acquires Neurogen.....II-35
FDA Seeks Additional Information for Seroquel XR sNDA in GAD Treatment.....II-35
AstraZeneca’s Seroquel XR™ Shows Improvement in GAD Symptoms.....II-35
Synosia Therapeutics Begins Phase II Efficacy Trial for Rufinamide.....II-35
1$100
   Ambien CR® Improves Chronic Insomnia in Patients with Co-morbid GAD.....II-36
AstraZeneca Files sNDA for Seroquel XR for Treating GAD.....II-36
Bionomics Concludes GMP Synthesis of BNC210.....II-36
1$100
   OJSC Pharmstandard to Take Over Afobazol® Trademark.....II-371$100
   AstraZeneca Plc. (UK).....II-38
Boehringer Ingelheim GmbH (Germany).....II-38
Bristol-Myers Squibb Company (US).....II-38
1$100
   Eli Lilly and Company (US).....II-39
F. Hoffmann-La Roche Ltd. (Switzerland).....II-39
1$100
   Forest Laboratories, Inc. (US).....II-40
GlaxoSmithKline Plc. (UK).....II-40
H. Lundbeck A/S (Denmark).....II-40
1$100
   Mylan, Inc. (US).....II-41
Neurocrine Biosciences, Inc. (US).....II-41
Pfizer, Inc. (US).....II-41
1$100
   Ratiopharm (Germany).....II-42
Sanofi (France).....II-42
UCB SA (Belgium).....II-42
Valeant Pharmaceuticals International (US).....II-42
1$100
   Watson Laboratories, Inc. (US).....II-431$100
   Table 5: World Recent Past, Current and Future Analysis for Anxiety Disorders by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-441$350
   Table 6: World Historic Review for Anxiety Disorders by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-451$350
   Table 7: World 15-Year Perspective for Anxiety Disorders by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-461$350
   A. Market Analysis.....III-1
Anxiety Disorders – A Major Health Burden.....III-1
Prevalence of Anxiety Disorders.....III-1
Table 8: US Prevalence of Anxiety Disorders by Type (includes corresponding Graph/Chart).....III-1
1$200
   Product Approvals and Launches.....III-22$100
   Strategic Corporate Developments.....III-43$125
   Select Players.....III-7
Bristol-Myers Squibb Company.....III-7
Eli Lilly and Company.....III-7
1$75
   Forest Laboratories, Inc......III-8
Mylan, Inc......III-8
Neurocrine Biosciences, Inc......III-8
1$75
   Pfizer, Inc......III-9
Valeant Pharmaceuticals International.....III-9
Watson Laboratories, Inc......III-9
1$75
   B. Market Analytics.....III-10
Table 9: The US Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes correspondingGraph/Chart).....III-10
1$200
   Table 10: The US Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-111$200
   A. Market Analysis.....III-12
Product Approval.....III-12
1$75
   B. Market Analytics.....III-13
Table 11: European Recent Past, Current & Future Analysis for Anxiety Disorders by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-13
1$200
   Table 12: European Historic Review for Anxiety Disorders Market by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-141$200
   Table 13: European 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-151$200
   A. Market Analysis.....III-16
Clinical Trials/Product Approvals.....III-16
Select Player.....III-16
1$75
   B. Market Analytics.....III-17
Table 14: French Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-17
1$200
   Table 15: French Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
Product Approval.....III-19
Select Players.....III-19
1$75
   B. Market Analytics.....III-20
Table 16: German Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-20
1$200
   Table 17: German Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Select Player.....III-22
Polifarma SpA.....III-22
B. Market Analytics.....III-22
Table 18: Italian Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-22
1$200
   Table 19: Italian Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-231$200
   A. Market Analysis.....III-24
An Overview of the Market Opportunity.....III-24
Table 20: Prevalence of Depression and Anxiety Disorders in the UK (2006): Percentage of Adult Population (16-75 Years) Affection by Condition (includes corresponding Graph/Chart).....III-24
1$200
   Product Approvals/Clinical Trials.....III-251$75
   Select Players.....III-261$75
   B. Market Analytics.....III-27
Table 21: The UK Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-27
1$200
   Table 22: The UK Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-281$200
   Market Analytics.....III-29
Table 23: Spanish Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-29
1$200
   Table 24: Spanish Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-301$200
   A. Market Analysis.....III-31
Strategic Corporate Development.....III-31
Select Players.....III-31
2$100
   B. Market Analytics.....III-33
Table 25: Rest of European Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-33
1$200
   Table 26: Rest of European Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-341$200
   A. Market Analysis.....III-35
Anxiety and Depression – A Major Debilitating Condition in Australia.....III-35
Table 27: 12-Month Prevalence of Anxiety Disorders in Australia by Age Group (2006) (includes corresponding Graph/Chart).....III-35
1$200
   Strategic Corporate Development.....III-36
Select Player.....III-36
1$75
   B. Market Analytics.....III-37
Table 28: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-37
1$200
   Table 29: Asia-Pacific Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-381$200
   A. Market Analysis.....III-39
Product Approval.....III-39
Select Player.....III-39
Ranbaxy Egypt Ltd. (Egypt).....III-39
1$75
   B. Market Analytics.....III-40
Table 30: Rest of World Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-40
1$200
   Table 31: Rest of World Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-411$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com